The global plasma therapy market is expected to grow from USD 135.6 Million in 2016 to USD 297.6 Million by 2021, at a CAGR of 14.0% from 2016 to 2021. The global market is segmented on the basis of type, source, application, end user, and region.

On the basis of type, the plasma therapy market is segmented into pure PRP, leucocyte-rich PRP, platelet-rich fibrin (PRF), and leukocyte-rich fibrin (L-PRF). The pure PRP segment is estimated to account for the largest share of the global market in 2016. One of the most significant factors driving the growth of this market includes the effective results of pure PRP therapy. However, lack of reimbursement policies and varying prices of plasma therapy are hindering the growth of the market.

On the basis of source, the market is segmented into autologous and allogenic. The autologous segment is estimated to account for the largest share of the global market in 2016. Awareness of plasma therapy and its acceptance as a suitable remedy for healing of bones and other tissues are driving the growth of the autologous source segment of the market.

Based on application, the plasma therapy market is segmented into orthopedics, dermatology, dental, cardiac muscle injury, nerve injury, and others. The orthopedic segment is further segmented into arthritis, chronic tendinitis, and bone repair & regeneration. Similarly, the dermatology segment is further segmented into androgenic alopecia and plastic surgery. The dermatology segment is expected to grow at the highest CAGR from 2016 to 2021, owing to the increasing number of dermatological disorders.

On the basis of end user, the market is classified into hospitals & clinics and research institutions. The hospitals & clinics segment is estimated to account for the largest share of the global market in 2016. This large share is mainly attributed to rise in healthcare expenditure and increase in the use of PRP products in hospitals.

Geographically, the market is led by North America, followed by Europe, Asia-Pacific, and rest of the world (RoW). Growth in the global market is primarily driven by the increase in aging population and rise in the number of orthopedic disorders.

This report aims to provide insights into the global plasma therapy market. It provides valuable information on plasma types, sources, applications, and end users in the market. Furthermore, it also provides a regional analysis of the market. Leading players are profiled in the report to study their product offerings and understand the strategies undertaken by them to sustain their competitive position in this market.

The above mentioned information would benefit buyers by helping them understand the market dynamics. In addition to this, it will also enable firms to understand the trends in this market and better position themselves to capitalize growth opportunities.

This report categorizes the plasma therapy market into the following segments:

By Type

Pure PRP

Leucocyte-rich PRP

Pure Platelet-rich Fibrin (PRF)

Leukocyte-rich Fibrin (L-PRF)

By Source

Autologous

Allogenic

By Application

Orthopedics

Arthritis

Chronic Tendinitis

Bone Repair & Regeneration

Dermatology

Androgenic Alopecia

Plastic Surgery

Dental

Cardiac Muscle Injury

Nerve Injury

Others

By End User

Hospitals & Clinics

Research Institutions

By Region

North America

U.S.

Canada

Europe

Germany

France

Italy

U.K.

Spain

RoE

Asia-Pacific

India

China

Japan

RoA

Rest of the World (RoW)

Customization Options:

Company Information: Detailed company profiles of five or more market players

Opportunities Assessment: A detailed report underlining various growth opportunities presented in the market

The global plasma therapy market comprises various types of platelet-rich plasma that are used by hospitals & clinics and several research institutions. Rise in the number of orthopedic disorders associated with trauma and aging led to the increased demand for minimally-invasive therapies. This has further contributed to the increased demand for PRP in orthopedic, dermatology, nerve injury, cardiac muscle injury, and dental applications.

This market is driven by several factors such as prevalence of orthopedic disorders such as arthritis and increase in healthcare expenditure. On the other hand, stringent regulatory policies and lack of awareness about platelet-rich therapy are factors restraining the growth of the expected to grow from USD 135.6 Million in 2016 to USD 297.6 Million by 2021, at a CAGR of 14.0% during the forecast period.

On the basis of type, the plasma therapy market is segmented into pure PRP, leucocyte-rich PRP, pure platelet-rich fibrin (PRF), and leukocyte-rich fibrin (L-PRF). The pure PRP segment is estimated to account for the largest share of the global market in 2016. Whereas, the leucocyte-rich PRP segment of the market is expected to grow at the highest CAGR from 2016 to 2021.

Based on source, the plasma therapy market is segmented into autologous and allogenic. The autologous segment is estimated to account for the largest share of the global market in 2016. Prevalence of orthopedic disorders such as arthritis and tendinitis has propelled the demand for advanced treatment options and development of minimally-invasive therapies. This in turn has contributed to the growth of the market.

Based on application, the market is segmented into dermatology, cardiac muscle injury, dental, nerve injury, and others. The orthopedic segment is further segmented into arthritis, chronic tendinitis, and bone repair & regeneration. Similarly, the dermatology segment is further segmented into androgenic alopecia and plastic surgery. The dermatology application segment is expected to grow at the highest CAGR from 2016 to 2021, owing to increase in the number of cosmetic procedures.

Based on end user, the plasma therapy market is segmented into hospitals & clinics and research institutions. The hospitals & clinics segment is estimated to account for the largest share of the global market in 2016. Rise in healthcare spending has resulted in the increasing use of PRP in hospitals & clinics.